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↑ What is "already known" in this topic: {#box1}
========================================

Nosocomial infections (NIs) represent a serious public health concern worldwide. Increased prevalence of NIs in some cases leads to patient's arbitrary use of drugs, causing serious health hazards as well as significant problems such as drug resistance and death in patients.

→ What this article adds: {#box2}
=========================

This study aimed to inform and assess the prevalence of NIs in Iran using a meta-analytic approach. Based on the randomeffects model, the overall prevalence of NIs in Iran was 4.5%. Proper training of healthcare staff in hospital, can play an important role in reducing NIs spreading in Iran.

Introduction {#s1}
============

Nosocomial infections (NIs) represent a serious public health concern worldwide ([@R1]), and, especially, in developing countries where, due to financial constraints, it is difficult to control ([@R2], [@R3]). Increased prevalence of NIs in some cases leads to patient's arbitrary use of drugs, causing serious health hazards as well as other problems such as drug resistance and death in patients ([@R4]). Worldwide, about 8.7% of hospitalized patients are at risk of exposure to NIs which considered as hospital-acquired infections and can complicate certain conditions such as cancer, organ transplant, and surgery, and also increasing mortality rate. As such, NIs generate a high societal burden, taking into account the costs for treatment, the increased length of hospital stay and the related mental and emotional stress ([@R5]).

Due to the wide variation of health-care systems in different countries, numerous reports have reported varying nosocomial infection rates ([@R6], [@R7]). The World Health Organization (WHO) carried out an epidemiological study conducted in 14 countries worldwide and found that the overall prevalence of NIs was 8.7% (ranging from 5.0% in North America and in Europe to 40.0% in Asia, Latin America, and Sub-Saharan Africa) ([@R7]). The knowledge of the epidemiology of NIs is crucial in establishing programs for controlling this acquired infection in hospitals, implementing effective and reliable plans ([@R8]).

Iran represents one of the developing countries, which faces with the issue of NIs imposing a high economic onus, in terms of high costs annually for the Ministry of Health (MoH) and private hospital managers. Several studies have been performed in different parts of the country related to the epidemiology of nosocomial infections. These studies can be valuable for healthcare workers and managers in developing an effective control program. This study aimed to review and assess the prevalence of NIs in Iran using a meta-analytic approach.

Methods {#s2}
=======

Literature search {#s2-0-1}
-----------------

The results and their analysis in this study were reported according to the PRISMA guidelines (Appendix 1) ([@R9]). Embase, PubMed/MEDLINE via Ovid, Web of Science, Scopus and Google Scholar as well as national Iranian databases, including SID, Magiran, and Irandoc, with medical subject headings (MeSH) terms and a proper use of keywords. The search strategy was as follows: (Nosocomial Infections OR Hospital Infections OR Healthcare Associated Infections OR Cross Infections) AND Iran. Articles written in Farsi and English were searched and a time filter (between January 2000 and December 2017) applied. Reference lists of articles as well as national and international conferences related to the topic were also searched.

Inclusion and exclusion criteria {#s2-0-2}
--------------------------------

Inclusion criteria were: 1) population-based observational studies reporting the prevalence of NIs, 2) cross-sectional, retrospective and case-control studies, and 3) pertinent studies with clear and detailed data. Case reports, case series, letters to editor, editorials, commentaries, reviews and clinical trials as well as studies not calculating the prevalence of NIs , as well as studies not calculating the prevalence of NIs were excluded.

Data extraction {#s2-0-3}
---------------

From included papers, two authors independently extracted following data: first author, year of publication, sample size, number of positive cases detected, age, region, the geography of the study, study design, and prevalence rate. Disagreement between them was solved through discussion or including a third person as a judge.

Quality of studies {#s2-0-4}
------------------

To check the methodological quality of included studies, the strengthening the reporting of observational studies in epidemiology (STROBE) checklist was used ([@R10]), categorizing the studies into three groups of high, medium and low quality.

Statistical analysis {#s2-0-5}
--------------------

To determine the pooled prevalence, the stochastic DerSimonian-Laird model was used, computing the effect size with its 95% confidence interval (CI) and pictorially representing it with a Forest plot. To examine the heterogeneity among studies, the I^2^ test were conducted ([@R11]). To further investigate the source of heterogeneity, meta-regression analyses stratified by publication year, sample size and duration of hospitalization in the hospital were carried out. The sensitivity analysis was performed to ensure the stability and robustness of results. Subgroup analyses were performed based on study quality, geographic areas, sample size, year of publication, type of infection, and hospital wards. The cumulative meta-analysis was performed based on year of publication. Egger's test for publication bias was carried out ([@R12]). All analyses were performed using the commercial software Comprehensive Meta-Analysis Ver.2 (Biostat, NJ, USA). All figures with p\<0.05 were considered statistically significant.

Results {#s3}
=======

Selected studies {#s3-0-1}
----------------

Finally, after an initial search, removing duplicates and checking the title and abstract of studies, 52 studies were selected based on inclusion and exclusion criteria ([@R13]-[@R64]). [Fig. 1](#F1){ref-type="fig"} shows the process of finding and selecting studies.
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The total sample size consisted of 8,989,980 subjects. [Table 1](#T1){ref-type="table"} shows the main characteristics of the included studies.

###### The main characteristics studies included‏

  -------------------- ------ --------- ------------------------ ------------------------- ------------ ----------------------- --------------------- ---------------
  First Author         Year   Sample    Average Length of Stay   Common infection          Place        Common Bacteria         Hospital unit         Quality study
  Hajibagheri          2003   160       16                       Pneumonia                 Sanandaj     Klebsiella pneumoniae   NA                    High
  Askarian             2003   170       19                       wound infection           Shiraz       NA                      NA                    High
  Askarian             2003   1483      7                        Surgical Site Infection   Shiraz       NA                      Surgery department    low
  Sadeghzadeh          2005   150       NA                       Urinary tract infection   Zanjan       Escherichia coli        ICU                   High
  Soltani Arabshahi    2005   810       17                       Surgical Site Infection   Tehran       NA                      Surgery department    Medium
  Rahbar               2005   6492      NA                       Bloodstream infections    Orumieh      Staphylococcus          Neonatal ward         Medium
  Sadeghifard          2006   5572      NA                       Urinary tract infection   Elam         Escherichia coli        Surgery department    Medium
  Ekrami               2007   182       NA                       wound infection           Ahvaz        Pseudomonas             NA                    Medium
  Ghazvini             2008   971       12                       Bloodstream infections    Mashhad      Staphylococcus          NICU                  Medium
  Lahsaeizadeh         2008   2667      NA                       Surgical Site Infection   Shiraz       NA                      Surgery department    High
  Ghorban Alizadegan   2008   3974      2                        Respiratory Infection     Tehran       Staphylococcus          ICU                   Medium
  Hassanzadeh          2009   89        16                       Urinary tract infection   Shiraz       Pseudomonas             ICU                   High
  Asl                  2009   102       17                       Pneumonia                 Tehran       Staphylococcus          PICU                  Medium
  Mohammadimehr        2009   165       20                       Pneumonia                 Tehran       Klebsiella pneumoniae   NA                    Medium
  Amini                2009   691       27                       Respiratory Infection     Tehran       Acinetobacter           ICU                   Medium
  Sohrabi              2009   23816     NA                       Urinary tract infection   Shahrod      Escherichia coli        ICU                   Medium
  Darvishpour          2010   270       NA                       NA                        NA           Enterobacter            ICU                   High
  Aletayyeb            2010   1604      16                       Pneumonia                 Ahvaz        Klebsiella pneumoniae   Neonatal ward         Medium
  Nadi                 2011   353       4                        Pneumonia                 Hamadan      Klebsiella pneumoniae   ICU                   Medium
  Tabatabaei           2011   428       23                       Urinary tract infection   Tehran       Escherichia coli        PICU                  High
  Amini                2011   691       NA                       Pneumonia                 Tehran       Acinetobacter           ICU                   Medium
  Ghorbani             2011   772       NA                       Urinary tract infection   Ahvaz        Pseudomonas             ICU                   Medium
  Askarian             2011   4013      NA                       Urinary tract infection   Shiraz       NA                      NA                    Medium
  Larypoor             2011   21054     NA                       Urinary tract infection   Qom          Escherichia coli        ICU                   low
  Masoumi Asl          2011   6616520   NA                       Urinary tract infection   NA           Pseudomonas             NA                    Medium
  Mobaien              2012   353       NA                       Urinary tract infection   Hamadan      Staphylococcus          ICU                   High
  Soltani              2012   464       NA                       Bloodstream infections    Tehran       Staphylococcus          ICU                   Medium
  Alaghehbandan        2012   677       21                       NA                        Tehran       Pseudomonas             NA                    High
  Pourakbari           2012   1497      8                        Respiratory Infection     Tehran       Staphylococcus          Children\'s section   low
  Barak                2012   3254      27                       Sepsis                    Ardabil      Klebsiella pneumoniae   NICU                  Medium
  Riahin               2012   3400      NA                       Surgical Site Infection   Qom          Staphylococcus          Surgery department    Medium
  Askarian             2012   3450      NA                       Bloodstream infections    Shiraz       NA                      Surgery department    Medium
  Assar                2012   9407      NA                       Urinary tract infection   Ahvaz        Enterobacter            ICU                   Medium
  Zahraei              2012   1879356   NA                       Urinary tract infection   NA           NA                      ICU                   low
  Askarian             2013   4013      NA                       Urinary tract infection   Shiraz       NA                      NA                    low
  Abdoli Oskouie       2013   7744      4                        Urinary tract infection   Tabriz       Staphylococcus          NICU                  Medium
  Akbari               2013   25776     22                       Respiratory Infection     Orumieh      Escherichia coli        ICU                   High
  Masoumi Asl          2013   47380     NA                       Urinary tract infection   NA           Escherichia coli        Burn unit             low
  Hamedi               2014   811       NA                       Urinary tract infection   Mashhad      Pseudomonas             PICU                  low
  Hoseini              2014   3129      10                       Pneumonia                 Tabriz       Staphylococcus          NICU                  High
  Behzadnia            2014   34556     NA                       wound infection           Mazandaran   Pseudomonas             NA                    Medium
  Davoudi              2014   57122     8                        wound infection           Mazandaran   Pseudomonas             Burn unit             low
  Shakib               2015   750       2                        NA                        Sanandaj     Klebsiella pneumoniae   ICU                   low
  Basiri               2015   1000      13                       Bloodstream infections    Hamadan      Escherichia coli        NICU                  Medium
  Shojaei              2015   12221     NA                       Surgical Site Infection   Qom          Pseudomonas             ICU                   low
  Lavakhamseh          2015   32400     NA                       Urinary tract infection   Sanandaj     Escherichia coli        Woman\'s ward         Medium
  Salmanzadeh          2015   15779     NA                       Surgical Site Infection   Ahvaz        Staphylococcus          ICU                   low
  Bijari               2015   36222     NA                       Pneumonia                 NA           Klebsiella pneumoniae   ICU                   low
  Tabatabaei           2015   16140     NA                       Respiratory Infection     Zahedan      Acinetobacter           ICU                   High
  Lavakhamseh          2015   32400     NA                       Urinary tract infection   Sanandaj     E. coli                 Woman\'s ward         Medium
  Darvishpoor          2016   1300      2                        Surgical Site Infection   Torbat       NA                      NA                    low
  Kazemian             2016   62601     NA                       Urinary tract infection   Ardabil      Escherichia coli        ICU                   High
  Falahi               2017   35979     NA                       Pneumonia                 Mashhad      Acinetobacter           ICU                   High
  -------------------- ------ --------- ------------------------ ------------------------- ------------ ----------------------- --------------------- ---------------

The overall prevalence of nosocomial infections in Iran {#s3-0-2}
-------------------------------------------------------

Based on the random-effects model, the overall prevalence of NIs in Iran was 4.5% \[95% CI: 3.5 to 5.7\] with a high, statistically significant heterogeneity (I^2^=99.82). [Fig. 2](#F2){ref-type="fig"} shows the overall prevalence.
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Sensitivity analysis {#s3-0-3}
--------------------

A sensitivity analysis was performed to ensure the stability results. After removing each study, results did not change. Appendix 2 shows the sensitivity analysis.

Cumulative meta-analysis {#s3-0-4}
------------------------

A cumulative meta-analysis of the included studies was performed based on year of publication and the results did not change. Appendix 3 shows the cumulative meta-analysis.

Sub-group analysis {#s3-0-5}
------------------

[Table 2](#T2){ref-type="table"} shows the results of the different sub-group analyses according to the quality of studies, geographic regions, sample size, year of publication, type of infection, and hospital wards.

###### The results of sub-group analyses

  ------------------------------------ ------------- --------------------- -------- -------- ------------------
  Variables                            No. studies   Prevalence%\          I2 (%)   p        No. participants
                                                     ( 95% CI)                               

  Quality of studies                                                                         

  High                                 14            7.2% (4-12.6)         99.54%   0.0001   148589

  Medium                               25            5.2% (2.9-9)          99.82%   0.0001   6762403

  Low                                  13            2% (1.1-3.6)          99.75%   0.0001   2078988

  Regional                                                                                   

  Center                               13            7.1% (3.2-15)         99.43%   0.0001   46174

  East                                 8             1.4 (0.9-2.2)         98.49%   0.0001   147639

  North                                2             0.4% (0.1-2.4)        99.42%   0.0001   91678

  South                                12            8.8% (4.8-15.7)       99.41%   0.0001   43629

  West                                 13            5.7% (3.6-8.8)        99.34%   0.0001   117334

  Several regional                     4             1.5% (1.1-2.1)        99.85%   0.0001   8543526

  Sample size                                                                                

  ≤1500                                24            13.3% (9.6-18.2)      97.79%   0.0001   14339

  \>1500                               28            17% ([@R13]-[@R22])   99.84%   0.0001   8975641

  Year of publication                                                                        

  2000-2005                            6             12.8% (8.8-18.2)      96.00%   0.0001   9265

  2006-2011                            19            7.6% (3.7-14.8)       99.78%   0.0001   6683934

  2012-2017                            27            2.4% (1.6-3.8)        99.82%   0.0001   2296781

  Common infections                                                                          

  Wound                                4             4% (3-3.6)            99.76%   0.0001   92030

  Bloodstream                          5             9% (5.4-14.6)         98.33%   0.0001   12377

  NA                                   3             15.8% (9.2-25.9)      94.99%   0.0001   1697

  Pneumonia                            9             7.1% (3-15.6)         99.50%   0.0001   78405

  Respiratory                          5             2.3% (0.8-6.6)        99.38%   0.0001   48078

  Sepsis                               1             1.3% ([@R1]-[@R7])    \-       \-       3254

  Surgical site                        7             4.4% (1.7-10.9)       99.55%   0.0001   37660

  Urinary tract                        18            3.1% (2.3-4.2)        99.85%   0.0001   8716479

  Common infection in hospital units                                                         

  Burn unit                            2             1% (0.8-1.1)          82.49%   0.0001   104502

  Children\'s section                  1             3.3% (2.5-4.4)        \-       \-       1497

  ICU                                  22            3.9% (2.3-6.5)        99.83%   0.0001   2146908

  Others                               10            7.1% (2.3-20.3)       99.80%   0.0001   6661756

  Neonatal                             2             6.4% (3.1-12.7)       97.19%   0.0001   8096

  NICU                                 5             2.9% (1.3-6.3)        98.36%   0.0001   16098

  PICU                                 3             5.9% (2-16.6)         94.39%   0.0001   1341

  Surgery department                   6             8.5% (5.8-12.4)       98.19%   0.0001   17382

  Woman's ward                         1             1(0.9-1.1)            \-       \-       32400

  Common bacteria                                                                            

  Klebsiella pneumonia                 7             6.6% (2.1-19.6)       99.46%   0.0001   42508

  Escherichia coli                     10            2.2% (1.1-4.2)        99.67%   0.0001   220177

  Staphylococci                        11            5.4% (2.9-9.8)        99.29%   0.0001   43905

  Pseudomonas                          9             4.9% (2-11.3)         99.78%   0.0001   6722950

  Acinetobacter                        4             3.5% (1-10.8)         99.52%   0.0001   53501

  Enterobacter                         2             7.3% (1.3-31.4)       99.04%   0.0001   9677

  Other infections                     9             5.3% (1.5-16.9)       99.90%   0.0001   1897262

  Gram bacteria                                                                              

  Positive                             10            5.1% (2.5-10.2)       99.23%   0.0001   37413

  Negative                             32            4% (2.8-5.7)          99.77%   0.0001   7048813

  NA                                   10            5.6% (1.7-16.7)       99.92    0.0001   1903754
  ------------------------------------ ------------- --------------------- -------- -------- ------------------

Meta-regression {#s3-0-6}
---------------

[Table 3](#T3){ref-type="table"} shows the results of the meta-regression analysis.

###### Results of the meta-regression

  ------------------------ ------------ ------------------ ------------- --------- ------
  Moderator                No studies   No. participants   Coefficient   Z-value   p
  Year of publication      52           8,989,980          -0.06         -24.51    0.00
  Sample size of studies   52           8,989,980          -0.00         -67.90    0.00
  Average length of stay   23           113,249            0.02          9.23      0.00
  ------------------------ ------------ ------------------ ------------- --------- ------

Publication bias {#s3-0-7}
----------------

Egger's test was carried out to assess publication bias ([Fig. 3](#F3){ref-type="fig"}). An evidence of publication bias was found (p=0.00)
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Discussion {#s4}
==========

This study was a comprehensive study on the prevalence of NIs in Iran using a systematic review and meta-analytic approach. The prevalence of NIs in Iran was found as 4.5% (95% CI: 3.5-5.7). Hospital infection rates range between 3.5% and 12% in developed countries and between 5.7% and 19.1% in developing countries ([@R7]), calling for the urgent need of better allocating resources and implementing a program for controlling infections ([@R65]). Differences in NIs rates among countries may not only reflect a socio-economical feature of each country but also depend on criteria and diagnostic tests used to detect infections, as well as on the different reporting systems and their quality ([@R66]).

We found that bloodstream infections, surgical site infections, and pneumonia were the most common NIs observed ([@R67]). Hospital-acquired pneumonia is directly related to air conditioning systems. In many developing countries due to lack of proper facilities, the installed ventilation systems may increase pneumonia rate ([@R68]). Studies have shown that surgical infection rates vary between 10% and 20%, and are mainly due to Staphylococcus aureus ([@R69]). In cases of complications, wound healing is delayed, the possibility of further surgery increases, and patients have to be treated with antibiotics. This increases the length of hospital stay and the health-related expenditure ([@R70]).

In our study, most infections occurred in the surgical ward. A study carried out in America reported a 2-5% rate ([@R71]), while a meta-analysis of surgical infection rate estimated a pooled prevalence of 3.7% ([@R72]). Surgical infections are particularly challenging ([@R73]). Identifying patients who are prone to such infections could minimize the incidence of nosocomial infections and reduce their burden in terms of deaths ([@R71]).

Further, our study computed a higher effect-size of infections caused by Gram-positive bacteria. A study computed a prevalence of these infections of about 5% ([@R3]). Similar results were found by other scholars ([@R74], [@R75]). In the ICU, a significant amount of infections are due to Gram-positive bacteria, and this trend is increasing ([@R76]).

In the present study, a high rate of infections caused by Klebsiella pneumoniae (urinary tract , respiratory tract , and bloodstream infections) was found ([@R77]). This is particularly alarming in that the organism can become resistant to Carbapenem, which leads to increased use of Colistin, absorbing higher costs ([@R78]). Moreover, our study showed a strong correlation between length of stay in the hospital and hospital infections rate, in agreement with other studies ([@R79]-[@R81]). Based on geographical regions of Iran, the south of the country reported the highest incidence of NIs (8.8%), due to weather conditions, being warm and dry, with high air temperature and humidity. The prevalence of NIs can vary according to the specific month of the year ([@R82]).

Meta-regression analysis based on year of publication showed a significant decreasing trend over the years, which may be due to the recent implementation of health promotion programs ([@R83]). Despite some strengths (including the systematic approach, and the robustness of findings as proven by the meta-regressions and by the sub-group, cumulative, and sensitivity analyses), some limitations of this study should be properly recognized. First, the heterogeneity was significantly high. This could reflect methodological differences among studies. Moreover, insufficient information was available to stratify the prevalence by gender. Further, in some provinces of Iran, epidemiological studies related to the prevalence of NIs were missing and, therefore, urgently needed.

Conclusion {#s5}
==========

The prevalence of NIs in Iran was determined as 4.5%. Preventing and reducing hospital infections can significantly impact on reducing mortality and health-related costs tor. Implementing ad hoc programs, such as training healthcare staff in hospital, can play an important role in reducing spread of infections. The use of appropriate and advanced features for secure hospital environment is a major contribution to the decrease of NIs. Health policy-makers in Iran can help reduce hospital infections by implementing appropriate policies, such as educational programs and improving the quality of surveillance system.
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